Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125070 (US8765733, 59) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet  | PC cid PC sid UniChem Similars | US Patent | 1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125072 (US8765733, 61) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125073 (US8765733, 64) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125057 (US8765733, 5) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125068 (US8765733, 55) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125061 (US8765733, 46) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125066 (US8765733, 53) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125059 (US8765733, 24) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125058 (US8765733, 6) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 11 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125063 (US8765733, 49) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 12 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125071 (US8765733, 60) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 20 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125055 (US8765733, 3) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 20 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125056 (US8765733, 4) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 26 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125065 (US8765733, 52) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 46 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125064 (US8765733, 51) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 50 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125074 (US8765733, 63) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 55 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125067 (US8765733, 54) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 76 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125060 (US8765733, 45) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 80 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125069 (US8765733, 57) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 85 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125062 (US8765733, 48) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 87 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM125054 (US8765733, 1) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 102 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of 2 substance additions. First the compounds to be tested (10 μM) are pipetted onto the cells and the Ca2+ influx i... | US Patent US8765733 (2014) BindingDB Entry DOI: 10.7270/Q2BZ64QQ | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
